MedPath

Pressure Ulcer Prevention: a Turn and Positioning System Combined With Incontinence Care and Tailored/Standard Repositioning

Not Applicable
Completed
Conditions
Pressure Ulcers
Incontinence-associated Dermatitis
Interventions
Device: The Prevalon® Turn and Position System 2.0
Procedure: A protocol tailored to individual risk factors
Device: Comfort Shield® barrier cream cloths
Registration Number
NCT02690753
Lead Sponsor
University Ghent
Brief Summary

The prevalence of pressure ulcer in hospitals is 7,3% - 23%. The primary etiological factors are pressure or pressure combined with shear. Prevention is very important and comprises: preventive skin care including cleansing and protecting the skin from exposure to moisture, the systematic repositioning of the patient, the offloading of the heels from the surface of the bed, the use of adequate bed support surfaces and an adequate nutritional status. The development and implementation of a risk based prevention plan for individuals identified as being at risk is strongly recommended. Limited compliance exists towards pressure ulcer preventive interventions. 25,5% of the patients at risk receive fully adequate prevention in bed. The reposition frequence is adequate in 55% of patients at risk. There is a lack of rigorously performed research addressing the effectiveness of devices or risk based protocols to improve compliance. Health care budgets are limited, priorities should be set in the allocation of health care resources.

The primary aim of this study is to compare the effectiveness of the turn and position system (Prevalon®Turn and Position System 2.0, SAGE) versus standard care to improve reposition frequence in patients at risk. The second aim is to compare the effectiveness of a tailored protocol versus standard care to improve reposition frequence in patients at risk. The third aim is to compare the effectiveness of standardized incontinence care versus standard care to improve the incidence of pressure ulcers and incontinence-associated dermatitis (IAD). Also a health economic evaluation will be performed.

The study will be performed in hospital setting (university and general hospitals) in a random sample of 226 patients aged \> 18 who are at risk of developing pressure ulcers. Patients will be recruited from three types of wards: intensive care units, geriatric wards and rehabilitation wards. Patients will be included in the study for a period of 8 days.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
227
Inclusion Criteria
  • At risk of developing pressure ulcers (Braden score < 17)
  • Maximum 24hours admitted on the ward at the time of inclusion
  • Expected lenght of stay: 8 days
  • Free of pressure ulcers category II, II, IV and incontinence-associated dermatitis (IAD) category 2 at the start of the study
Exclusion Criteria
  • Patients with no active or supportive therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard repositioning + Standardised incontinence care + TAPThe Prevalon® Turn and Position System 2.0Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
Tailored repositioning + Standardised incontinence care + TAPA protocol tailored to individual risk factorsA protocol tailored to individual risk factors will be applied to patients at risk.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
Tailored repositioning + Standardised incontinence care + TAPThe Prevalon® Turn and Position System 2.0A protocol tailored to individual risk factors will be applied to patients at risk.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
Standard repositioning + Standardised incontinence care + TAPComfort Shield® barrier cream clothsInstead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
Tailored repositioning + Standardised incontinence care + TAPComfort Shield® barrier cream clothsA protocol tailored to individual risk factors will be applied to patients at risk.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
Primary Outcome Measures
NameTimeMethod
Turning compliance of nurses within the trial period as assessed by the researcher (unannounced)within 8 days after the start of the study

The researcher wil collect and administer data about turning compliance and compliance with the protocol

Secondary Outcome Measures
NameTimeMethod
Turning anglewithin 8 days after the start of the study

Per patient the researcher will measure two times the turning angle in which the patient is positioned.

Sacrum free of pressurewithin 8 days after the start of the study

Per patient the researcher will investigate two times if the sacrum is free of pressure while the patient is positioned.

Incidence of pressure ulcers and incontinence-associated dermatitiswithin 8 days after the start of the study
Comfort and preferences of the caregiverOn baseline and at day 8 (the end of the study)

Questions on comfort and preferences of the TAP, comfort shield barrier cream cloths and tailored repositioning will be assessed. At baseline these questions will assess the traditional care.

Comfort and tolerance of the patientAt day 8 (the end of the study)

Questions on comfort and tolerance of the TAP, comfort shield barrier cream cloths and repositioning will be assessed by the caregiver. At baseline these questions will assess the traditional care.

Cost-effectiveness of the prevention of pressure ulcersFor the duration of the study (8 days)

The following costs will be calculated to provide insight concerning cost-effectiveness:

Objective time analysis of repositioning (by using a chronometer), Subjective time analysis of repositioning, Daily consumption of comfort shield barrier cream cloths and microclimate body pads

Trial Locations

Locations (15)

AZ Oudenaarde

🇧🇪

Oudenaarde, Oost-Vlaanderen, Belgium

ZNA St. Elisabeth

🇧🇪

Antwerpen, Belgium

Imelda Ziekenhuis

🇧🇪

Bonheiden, Belgium

UZ Gent

🇧🇪

Gent, Oost-Vlaanderen, Belgium

AZ St. Maarten

🇧🇪

Duffel, Antwerpen, Belgium

AZ St. Dimpna

🇧🇪

Geel, Antwerpen, Belgium

ASZ Aalst

🇧🇪

Aalst, Belgium

AZ St. Jan Oostende

🇧🇪

Oostende, Belgium

AZ Delta Roeselare

🇧🇪

Roeselare, Belgium

AZ Nikolaas campus Beveren

🇧🇪

Beveren, Oost-Vlaanderen, Belgium

AZ Monica

🇧🇪

Antwerpen, Belgium

ZNA Hoge Beuken

🇧🇪

Antwerpen, Belgium

AZ St. Jan Brugge

🇧🇪

Brugge, Belgium

ASZ Geraardsbergen

🇧🇪

Geraardsbergen, Belgium

AZ Delta Menen

🇧🇪

Menen, Belgium

© Copyright 2025. All Rights Reserved by MedPath